Document:

Exhibit 4.4

   

  WARRANT AGREEMENT

   

  THIS WARRANT AGREEMENT (this “Agreement”), dated as of [•], 2021, is by and between Jackson Acquisition Company, a
    Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent,” also referred to herein as the “Transfer Agent”).

   

  WHEREAS, on [•], 2021, the Company entered into that certain Sponsor Warrants Purchase Agreement with RJ Healthcare SPAC, LLC,
    a Delaware limited liability company (the “Sponsor”), pursuant to which the Sponsor will purchase an aggregate of 5,666,667 warrants (or up to 6,266,667 warrants if the Over-allotment Option (as defined below) in connection with the Company’s
    Offering (as defined below) is exercised in full) simultaneously with the closing of the Offering (and the closing of the Over-allotment Option, if applicable), bearing the legend set forth in Exhibit B hereto (the “Private Placement Warrants”,
    which term includes up to an additional 1,000,000 additional Private Placement Warrants that may be issued upon conversion of Working Capital Loans (as defined below), as described in the next paragraph) at a purchase price of $1.50 per Private
    Placement Warrant. Each Private Placement Warrant entitles the holder thereof to purchase one share of Common Stock (as defined below) at a price of $11.50 per share, subject to adjustment as described herein;

   

  WHEREAS, in order to finance the Company’s transaction costs in connection with an intended initial merger, share exchange,
    asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses (a “Business Combination”), the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and
    directors may, but are not obligated to, loan the Company funds as the Company may require (“Working Capital Loans”), of which up to $1,500,000 of such loans may be convertible into up to an additional 1,000,000 Private Placement Warrants at a
    price of $1.50 per Private Placement Warrant;

   

  WHEREAS, the Company is engaged in an initial public offering (the “Offering”) of units of the Company’s equity
    securities, each such unit comprised of one share of Common Stock (as defined below) and one-third of one Public Warrant (as defined below) (the “Units”) and, in connection therewith, has determined to issue and deliver up to 11,500,000 warrants
    (including up to 1,500,000 warrants subject to the Over-allotment Option (as defined below)) to public investors in the Offering (the “Public Warrants” and, together with the Private Placement Warrants, the “Warrants”). Each whole Warrant
    entitles the holder thereof to purchase one share of Class A common stock of the Company, par value $0.0001 per share (“Common Stock”), for $11.50 per share, subject to adjustment as described herein. Only whole Warrants are exercisable. A
    holder of the Warrants will not be able to exercise any fraction of a Warrant;

   

  WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement
    on Form S-1, File No. 333-254727, including the prospectus contained therein (the “Prospectus”), for the registration, under the Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Public Warrants and the Common
    Stock included in the Units (such shares of Common Stock included in the Units, the “Public Shares”);

   

  WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in
    connection with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants;

   

  WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued
    and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

   

   

  
    1 

    
      
 

  

  
   

  WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of
    the Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.

   

  NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

   

  1.                 Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the
    Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

   

  2.                 Warrants.

   

  2.1             Form of Warrant. Each Warrant shall be issued in registered form only.

   

  2.2             Effect of Countersignature. If a physical certificate is issued, unless and until countersigned by the
    Warrant Agent pursuant to this Agreement, a Warrant shall be invalid and of no effect and may not be exercised by the holder thereof.

   

  2.3             Registration.

   

  2.3.1       Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”), for the
    registration of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations
    and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. Ownership of beneficial interests in the Public Warrants in book-entry form shall be shown on, and the transfer of such ownership shall be effected through,
    records maintained by institutions that have accounts with The Depository Trust Company (the “Depositary”) (such institution, with respect to a Warrant in its account, a “Participant”).

   

  If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company
    may instruct the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the
    Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each book-entry Public Warrant, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in
    physical form evidencing such Warrants, which shall be in the form annexed hereto as Exhibit A.

   

  Physical certificates, if issued, shall be signed by, or bear the facsimile signature of, the Chairman of the Company’s Board
    of Directors (the “Board”), Chief Executive Officer, President, Chief Financial Officer, Chief Accounting Officer, any Vice President, Treasurer or Secretary of the Company. In the event the person whose facsimile signature has been placed upon
    any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.

   

  2.3.2       Registered Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and
    the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any
    notation of ownership or other writing on any physical certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be
    affected by any notice to the contrary.

   

  
    2 

    
      
 

  

   

  2.4             Detachability of Warrants. The Common Stock and Public Warrants comprising the Units shall begin
    separate trading on the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday, Sunday or federal holiday, on which banks in New York City are generally open for normal business (a “Business Day”),

    then on the immediately succeeding Business Day following such date or earlier (the “Detachment Date”) with the consent of BofA Securities, Inc., but in no event shall the Common Stock and the Public Warrants comprising the Units be separately
    traded until (A) the Company has filed a current report on Form 8-K with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering, including the proceeds received by the Company from
    the exercise by the underwriter of its right to purchase additional Units in the Offering (the “Over-allotment Option”), if the Over-allotment Option is exercised prior to the filing of the Form 8-K, and (B) the Company issues a press release
    announcing when such separate trading shall begin. The Company will file the Form 8-K referred to in clause (A) of the preceding sentence promptly after the closing of the Offering and, if the Over-allotment Option is exercised following the filing of
    the initial Form 8-K, the Company will promptly file a second or amended current report on Form 8-K to provide updated financial information reflecting the exercise of the Over-allotment Option.

   

  2.5             No Fractional Warrants Other Than as Part of the Units. The Company shall not issue fractional Warrants
    other than as part of the Units, each of which is comprised of one share of Common Stock and one-third of one Public Warrant. If, upon the detachment of Public Warrants from the Units or otherwise, a holder of Warrants would be entitled to receive a
    fractional Warrant, the Company shall round down to the nearest whole number the number of Warrants to be issued to such holder.

   

  2.6             Private Placement Warrants. The Private Placement Warrants shall be identical to the Public Warrants,
    except that so long as they are held by the Sponsor or any of its Permitted Transferees (as defined below), the Private Placement Warrants: (i) may be exercised for cash or on a “cashless basis,” pursuant to subsection 3.3.1(c) hereof, (ii)
    including the shares of Common Stock issued or issuable upon exercise of the Private Placement Warrants, may not be transferred, assigned or sold until thirty (30) days after the completion by the Company of an initial Business Combination, (iii) shall
    only be redeemable by the Company pursuant to Section 6.2 if the Reference Value (as defined below) is less than $18.00 per share (subject to adjustment in accordance with Section 4 hereof) and (iv) shall not be redeemable by the
    Company pursuant to Section 6.1 hereof; provided, however, that in the case of (ii), the Private Placement Warrants and any shares of Common Stock issued upon exercise of the Private Placement Warrants held by the Sponsor or any
    of its Permitted Transferees may be transferred by the holders thereof:

   

  (a)              to the Company’s officers or directors, any affiliates or family members of any of the Company’s officers or
    directors, any members of the Sponsor, or any affiliates of the Sponsor;

   

  (b)              in the case of an individual, by gift to a member of the individual’s immediate family or to a trust, the
    beneficiary of which is a member of the individual’s immediate family, an affiliate of such person or to a charitable organization;

   

  (c)              in the case of an individual, by virtue of the laws of descent and distribution upon death of the individual;

   

  (d)              in the case of an individual, pursuant to a qualified domestic relations order;

   

  
    3 

    
      
 

  

   

  (e)              by private sales or transfers made in connection with the consummation of the Company’s initial Business
    Combination at prices no greater than the price at which the securities were originally purchased;

   

  (f)               in the event of the Company’s liquidation prior to the completion of the Company’s initial Business
    Combination;

   

  (g)              by virtue of the laws of the State of Delaware or the Sponsor’s limited liability company agreement upon
    dissolution of the Sponsor; or

   

  (h)              in the event of the Company’s completion of a liquidation, merger, share exchange, reorganization or other
    similar transaction which results in all of the holders of the Company’s Public Shares having the right to exchange their shares of common stock for cash, securities or other property subsequent to the completion of the Company’s initial Business
    Combination;

   

  (the transferees referred to in clauses (a) through (h) above are hereinafter called the “Permitted Transferees”); provided, however, that
    in the case of clauses (a) through (e) and clause (g), these Permitted Transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and the other provisions of the letter agreement dated as of [•], 2021 among the
    Company, the Sponsor and the officers and directors/director nominees of the Company party thereto and deliver such written agreement to the Company prior to or concurrently with the applicable transfer.

   

  3.                 Terms and Exercise of Warrants.

   

  3.1          Warrant Price. Each Warrant shall entitle the Registered Holder thereof, subject to the provisions of such
    Warrant and of this Agreement, to purchase from the Company the number of shares of Common Stock stated therein, at the price of $11.50 per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section

      3.1. The term “Warrant Price” as used in this Agreement shall mean the price per share (including in cash or by payment of Warrants pursuant to a “cashless exercise,” to the extent permitted hereunder) at which shares of Common Stock may be
    purchased at the time a Warrant is exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days (unless otherwise required
    by the Commission, any national securities exchange on which the Warrants are listed or applicable law); provided, that the Company shall provide at least three (3) Business Days prior written notice of such reduction to Registered Holders of
    the Warrants and, provided further that any such reduction shall be identical among all of the Warrants.

   

  3.2             Duration of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”)
    commencing on the later of: (i) the date that is thirty (30) days after the first date on which the Company completes its initial Business Combination, and (ii) the date that is twelve (12) months from the date of the closing of the Offering, and
    terminating at 5:00 p.m., New York City time, on the earliest to occur of: (x) the date that is five (5) years after the date on which the Company completes its initial Business Combination, (y) the liquidation of the Company in accordance with its
    amended and restated certificate of incorporation if the Company fails to complete its initial Business Combination, and (z) other than with respect to the Private Placement Warrants then held by the Sponsor or any Permitted Transferees with respect to
    a redemption pursuant to Section 6.1 hereof or, if the Reference Value (as defined in Section 6.3 below) equals or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof), Section 6.2 hereof (each,
    an “Inapplicable Redemption”), 5:00 p.m., New York City time, on the Redemption Date (as defined below) as provided in Section 6.3 hereof (the “Expiration Date”); provided, however, that the exercise of any Warrant
    shall be subject to the satisfaction of any applicable conditions, as set forth in subsection 3.3.2 below, with respect to an effective registration statement under the Securities Act or a valid exemption from registration being available.
    Except with respect to the right to receive the Redemption Price (as defined below) (other than with respect to Private Placement Warrants then held by the Sponsor or any Permitted Transferees in the case of an Inapplicable Redemption), each Warrant
    (other than a Private Placement Warrant then held by the Sponsor or any Permitted Transferees with respect to an Inapplicable Redemption) not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in
    respect thereof under this Agreement shall cease at 5:00 p.m. New York City time, on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; provided, that the Company
    shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall be identical in duration among all the Warrants.

   

  
    4 

    
      
 

  

   

  3.3             Exercise of Warrants.

   

  3.3.1       Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the
    Registered Holder thereof by surrendering it, at the office of the Warrant Agent, or at the office of its successor as Warrant Agent with the subscription form, as set forth in the Warrant, duly executed (or, in the case of a Warrant in book-entry
    form, by delivering the Warrant and providing the information on the subscription form in accordance with the Depositary’s procedures), and by paying in full the Warrant Price for each full share of Common Stock as to which the Warrant is exercised
    (including by cashless exercise) and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the shares of Common Stock and the issuance of such shares of Common Stock, as follows:

   

  (a)              in lawful money of the United States, in good certified check or wire payable to the Warrant Agent;

   

  (b)              [Reserved];

   

  (c)              with respect to any Private Placement Warrant, so long as such Private Placement Warrant is held by the
    Sponsor or a Permitted Transferee, by surrendering the Warrants for that number of shares of Common Stock equal to (i) if in connection with a redemption of Private Placement Warrants pursuant to Section 6.2 hereof, as provided in Section
      6.2 hereof with respect to a Make-Whole Exercise (as defined below) and (ii) in all other scenarios, the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of
    the “Sponsor Exercise Fair Market Value” (as defined in this subsection 3.3.1(c)) less the Warrant Price by (y) the Sponsor Exercise Fair Market Value. Solely for purposes of this subsection 3.3.1(c), the “Sponsor Fair Market Value”
    shall mean the average last reported sale price of the shares of Common Stock for the ten (10) trading days ending on the third (3rd) trading day prior to the date on
    which notice of exercise of the Private Placement Warrant is sent to the Warrant Agent;

   

  (d)              as provided in Section 6.2 hereof with respect to a Make-Whole Exercise; or

   

  (e)              as provided in Section 7.4 hereof.

   

  
    5 

    
      
 

  

   

  3.3.2       Issuance of Shares of Common Stock on Exercise. As soon as practicable after the exercise of any Warrant
    and the clearance of the funds in payment of the Warrant Price (if payment is pursuant to subsection 3.3.1(a)), the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the number
    of full shares of Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as
    applicable, for the number of shares of Common Stock as to which such Warrant shall not have been exercised. Notwithstanding the foregoing, the Company shall not be obligated to deliver any shares of Common Stock pursuant to the exercise of a Warrant
    and shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the shares of Common Stock underlying the Public Warrants is then effective and a prospectus relating thereto is
    current, subject to the Company’s satisfying its obligations under Section 7.4 or unless a valid exemption from registration is available. No Warrant shall be exercisable and the Company shall not be obligated to issue shares of Common Stock
    upon exercise of a Warrant unless the Common Stock issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the state of residence of the Registered Holder
    of the Warrants. Subject to Section 4.6, a Registered Holder of Warrants may exercise its Warrants only for a whole number of shares of Common Stock. The Company may require holders of Public Warrants to settle the Warrant on a “cashless basis”
    pursuant to Section 7.4. If, by reason of any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share of Common Stock, the Company
    shall round down to the nearest whole number, the number of shares of Common Stock to be issued to such holder.

   

  3.3.3       Valid Issuance. All shares of Common Stock issued upon the proper exercise of a Warrant in conformity with
    this Agreement shall be validly issued, fully paid and non-assessable.

   

  3.3.4       Date of Issuance. Each person in whose name any book-entry position or certificate, as applicable, for
    shares of Common Stock is issued shall for all purposes be deemed to have become the holder of record of such shares of Common Stock on the date on which the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the
    Warrant Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when the share transfer books of the Company or book-entry system
    of the Warrant Agent are closed, such person shall be deemed to have become the holder of such shares of Common Stock at the close of business on the next succeeding date on which the share transfer books or book-entry system are open.

   

  3.3.5       Maximum Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be
    subject to the provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to this subsection 3.3.5 unless he, she or it makes such election. If the election is made by a holder, the Warrant Agent
    shall not effect the exercise of the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the Warrant
    Agent’s actual knowledge, would beneficially own in excess of 9.8% or such other amount as the holder may specify (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes
    of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrant with respect to which the
    determination of such sentence is being made, but shall exclude shares of Common Stock that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise
    or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants)
    subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of
    the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, the holder may rely on the number of outstanding shares of Common Stock as
    reflected in (1) the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, current report on Form 8-K or other public filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3)
    any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days,
    confirm orally and in writing to such holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of equity securities
    of the Company by the holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum
    Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.

   

  
    6 

    
      
 

  

   

  4.                 Adjustments.

   

  4.1             Stock Dividends.

   

  4.1.1       Split-Ups. If after the date hereof, and subject to the provisions of Section 4.6 below, the number
    of outstanding shares of Common Stock is increased by a stock dividend payable in shares of Common Stock, or by a split-up of shares of Common Stock or other similar event, then, on the effective date of such stock dividend, split-up or similar event,
    the number of shares of Common Stock issuable on exercise of each Warrant shall be increased in proportion to such increase in the outstanding shares of Common Stock. A rights offering made to all or substantially all holders of the Common Stock
    entitling holders to purchase shares of Common Stock at a price less than the “Historical Fair Market Value” (as defined below) shall be deemed a stock dividend of a number of shares of Common Stock equal to the product of (i) the number of shares of
    Common Stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Common Stock) multiplied by (ii) one (1) minus the quotient of (x) the price per
    share of Common Stock paid in such rights offering divided by (y) the Historical Fair Market Value. For purposes of this subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Common Stock, in
    determining the price payable for Common Stock, there shall be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) “Historical Fair Market Value” means the volume
    weighted average price of the Common Stock during the ten (10) trading day period ending on the trading day prior to the first date on which the shares of Common Stock trade on the applicable exchange or in the applicable market, regular way, without
    the right to receive such rights.

   

  4.1.2       Extraordinary Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, pays
    to all or substantially all of the holders of shares of Common Stock a dividend or makes a distribution in cash, securities or other assets to the holders of the Common Stock on account of such shares of Common Stock (or other securities into which the
    Warrants are convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption rights of the holders of the Common Stock in connection with a proposed initial
    Business Combination, (d) to satisfy the redemption rights of the holders of Common Stock in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation to (A) modify the substance or timing of the
    Company’s obligation to allow redemption of Public Shares in connection with the Company’s initial Business Combination or (B) redeem 100% of the Public Shares if the Company does not complete the Business Combination within the time period required by
    the Company’s amended and restated certificate of incorporation, as amended form time to time, or (e) in connection with the redemption of Public Shares upon the failure of the Company to complete its initial Business Combination and any subsequent
    distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an “Extraordinary Dividend’), then the Warrant Price shall be decreased, effective immediately after the effective date of such
    Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend. For purposes of this
    subsection 4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash distribution which, when combined on a per share basis with the per share amounts of all other cash dividends and cash distributions paid on the Common Stock
    during the 365-day period ending on the date of declaration of such dividend or distribution, does not exceed $0.50 (as adjusted to appropriately reflect any of the events referred to in other subsections of this Section 4 but excluding cash
    dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of shares of Common Stock issuable on exercise of each Warrant), but only with respect to the amount of the aggregate cash dividends and cash
    distributions equal to or less than $0.50 per share (as adjusted if applicable).

   

  
    7 

    
      
 

  

   

  4.2             Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 4.6
    hereof, the number of outstanding shares of Common Stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Common Stock or other similar event, then, on the effective date of such consolidation,
    combination, reverse stock split, reclassification or similar event, the number of shares of Common Stock issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding shares of Common Stock.

   

  4.3             Adjustments in Warrant Price. Whenever the number of shares of Common Stock purchasable upon the
    exercise of the Warrants is adjusted, as provided in subsection 4.1.1 or Section 4.2 above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately prior to such adjustment by a fraction
    (x) the numerator of which shall be the number of shares of Common Stock purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of shares of Common Stock so purchasable
    immediately thereafter.

   

  4.4             Raising of the Capital in Connection with the Initial Business Combination. If (x) the Company issues
    additional shares of Common Stock or securities that are convertible into or exchangeable or exercisable for Common Stock for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective
    issue price of less than $9.20 per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Board and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any
    shares of Class B common stock, par value $0.0001 per share, of the Company held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent
    more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the
    volume-weighted average per share trading price of Common Stock during the twenty (20) trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”)

    is below $9.20 per share, the Warrant Price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described in Section 6.1 shall
    be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price and the $10.00 per share redemption trigger price described in Section 6.2 shall be adjusted (to the nearest cent) to be equal to the
    higher of the Market Value and the Newly Issued Price.

   

  
    8 

    
      
 

  

   

  4.5             Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization
    of the outstanding shares of Common Stock (other than a change under subsections 4.1.1 or 4.1.2 or Section 4.2 hereof or that solely affects the par value of such shares of Common Stock), or in the case of any merger or
    consolidation of the Company with or into another corporation or entity (other than a consolidation or merger in which the Company is the continuing corporation or entity and that does not result in any reclassification or reorganization of the
    outstanding shares of Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is
    dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the shares of Common Stock of the Company immediately theretofore
    purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or
    consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrants immediately prior to such event (the “Alternative Issuance”); provided,
    however, that (i) if the holders of the Common Stock were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities,
    cash or other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share by the holders of the Common Stock in such consolidation or
    merger that affirmatively make such election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders of the Common Stock (other than a tender, exchange or redemption offer made by the Company in
    connection with redemption rights held by stockholders of the Company as provided for in the Company’s amended and restated certificate of incorporation or as a result of the redemption of shares of Common Stock by the Company if a proposed initial
    Business Combination is presented to the stockholders of the Company for approval) under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule
    13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of
    any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor rule)) more than 50% of the outstanding shares of Common Stock, the holder of a Warrant shall
    be entitled to receive as the Alternative Issuance, the highest amount of cash, securities or other property to which such holder would actually have been entitled as a stockholder if such Warrant holder had exercised the Warrant prior to the
    expiration of such tender or exchange offer, accepted such offer and all of the Common Stock held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation of such tender or
    exchange offer) as nearly equivalent as possible to the adjustments provided for in this Section 4; provided, further, that if less than 70% of the consideration receivable by the holders of the Common Stock in the applicable
    event is payable in the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following
    such event, and if the Registered Holder properly exercises the Warrant within thirty (30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form 8-K filed with the
    Commission, the Warrant Price shall be reduced by an amount (in dollars) equal to the difference of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) (but in no event less than zero)
    minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of the applicable event based on the Black-Scholes Warrant Model for a Capped
    American Call on Bloomberg Financial Markets (assuming zero dividends) (“Bloomberg”). For purposes of calculating such amount, (1) Section 6 of this Agreement shall be taken into account, (2) the price of each share of Common Stock shall
    be the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event, (3) the assumed volatility shall be the 90 day volatility
    obtained from the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event, and (4) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a period
    equal to the remaining term of the Warrant. “Per Share Consideration” means (i) if the consideration paid to holders of the Common Stock consists exclusively of cash, the amount of such cash per share of Common Stock, and (ii) in all other
    cases, the amount of cash per share of Common Stock, if any, paid to the holders plus the volume weighted average price of the Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the
    applicable event. If any reclassification or reorganization also results in a change in shares of Common Stock covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3
    and this Section 4.4, as applicable. The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event will the Warrant Price be
    reduced to less than the par value per share issuable upon exercise of the Warrant.

   

  
    9 

    
      
 

  

   

  4.6             Notices of Changes in Warrant. Upon every adjustment of the Warrant Price or the number of shares of
    Common Stock issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the increase or decrease, if any, in the number of
    shares of Common Stock purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in Section
      4.1, 4.2, 4.3, 4.4 , 4.5, or 4.9 the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of
    the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

   

  4.7             No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the
    Company shall not issue fractional shares of Common Stock upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive
    a fractional interest in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to such holder.

   

  4.8      Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section

      4, and Warrants issued after such adjustment may state the same Warrant Price and the same number of shares of Common Stock as is stated in the Warrants initially issued pursuant to this Agreement; provided, however, that the
    Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or
    substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

   

  4.9             Other Events. In case any event shall occur affecting the Company as to which none of the provisions of
    the preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section

      4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the
    rights represented by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they determine that an adjustment is necessary, the terms of such adjustment; provided, however, that under no
    circumstances shall the Warrants be adjusted pursuant to this Section 4.9 as a result of any issuance of securities in connection with a Business Combination. The Company shall adjust the terms of the Warrants in a manner that is consistent
    with any adjustment recommended in such opinion.

   

  
    10 

    
      
 

  

   

  5.                 Transfer and Exchange of Warrants.

   

  5.1             Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any
    outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant
    representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. The Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.

   

  5.2             Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a
    written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of
    Warrants; provided, however, that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants
    in exchange thereof until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

   

  5.3             Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or
    exchange which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as part of the Units.

   

  5.4             Service Charges. No service charge shall be made for any exchange or registration of transfer of
    Warrants.

   

  5.5             Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to
    deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this Section 5, and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly
    executed on behalf of the Company for such purpose.

   

  5.6             Transfer of Warrants. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged
    only together with the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a transfer or exchange of such Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate
    also to transfer the Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6 shall have no effect on any transfer of Warrants on and after the Detachment Date.

   

  6.                 Redemption.

   

  6.1             Redemption of Warrants for Cash. Subject to Section 6.5 hereof, not less than all of the
    outstanding Warrants may be redeemed, at the option of the Company, at any time during the Exercise Period, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a
    Redemption Price of $0.01 per Warrant, provided that (a) the Reference Value equals or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof) and (b) there is an effective registration statement under the
    Securities Act covering the issuance of the shares of Common Stock issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.3 below).

   

  
    11 

    
      
 

  

   

  6.2             Redemption of Warrants for Common Stock. Subject to Section 6.5 hereof, not less than all of
    the outstanding Warrants may be redeemed, at the option of the Company, at any time during the Exercise Period, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a
    Redemption Price of $0.10 per Warrant, provided that (i) the Reference Value equals or exceeds $10.00 per share (subject to adjustment in compliance with Section 4 hereof) and (ii) if the Reference Value is less than $18.00 per share
    (subject to adjustment in compliance with Section 4 hereof), the Private Placement Warrants are also concurrently called for redemption on the same terms as the outstanding Public Warrants. During the 30-day Redemption Period in connection with
    a redemption pursuant to this Section 6.2, Registered Holders of the Warrants may elect to exercise their Warrants on a “cashless basis” pursuant to subsection 3.3.1 and receive a number of shares of Common Stock determined by reference to the
    table below, based on the Redemption Date (calculated for purposes of the table as the period to expiration of the Warrants) and the “Redemption Fair Market Value” (as such term is defined in this Section 6.2) (a “Make-Whole Exercise”).
    Solely for purposes of this Section 6.2, the “Redemption Fair Market Value” shall mean the volume weighted average price of the shares of Common Stock for the ten (10) trading days immediately following the date on which notice of
    redemption pursuant to this Section 6.2 is sent to the Registered Holders. In connection with any redemption pursuant to this Section 6.2, the Company shall provide the Registered Holders with the Redemption Fair Market Value no later
    than one (1) Business Day after the ten (10) trading day period described above ends. 

   

  	
           

        	
           

        	
          Redemption Fair Market Value of Common Stock ($)

        	
           

        
	
          Redemption Date (period to expiration of Warrants)

        	
           

        	
          <10.00

        	
           

        	
           

        	
          11.00

        	
           

        	
           

        	
          12.00

        	
           

        	
           

        	
          13.00

        	
           

        	
           

        	
          14.00

        	
           

        	
           

        	
          15.00

        	
           

        	
           

        	
          16.00

        	
           

        	
           

        	
          17.00

        	
           

        	
           

        	
          ≥18.00

        	
           

        
	
          60 months

        	
           

        	
           

        	
          0.261

        	
           

        	
           

        	
           

        	
          0.281

        	
           

        	
           

        	
           

        	
          0.297

        	
           

        	
           

        	
           

        	
          0.311

        	
           

        	
           

        	
           

        	
          0.324

        	
           

        	
           

        	
           

        	
          0.337

        	
           

        	
           

        	
           

        	
          0.348

        	
           

        	
           

        	
           

        	
          0.358

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          57 months

        	
           

        	
           

        	
          0.257

        	
           

        	
           

        	
           

        	
          0.277

        	
           

        	
           

        	
           

        	
          0.294

        	
           

        	
           

        	
           

        	
          0.310

        	
           

        	
           

        	
           

        	
          0.324

        	
           

        	
           

        	
           

        	
          0.337

        	
           

        	
           

        	
           

        	
          0.348

        	
           

        	
           

        	
           

        	
          0.358

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          54 months

        	
           

        	
           

        	
          0.252

        	
           

        	
           

        	
           

        	
          0.272

        	
           

        	
           

        	
           

        	
          0.291

        	
           

        	
           

        	
           

        	
          0.307

        	
           

        	
           

        	
           

        	
          0.322

        	
           

        	
           

        	
           

        	
          0.335

        	
           

        	
           

        	
           

        	
          0.347

        	
           

        	
           

        	
           

        	
          0.357

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          51 months

        	
           

        	
           

        	
          0.246

        	
           

        	
           

        	
           

        	
          0.268

        	
           

        	
           

        	
           

        	
          0.287

        	
           

        	
           

        	
           

        	
          0.304

        	
           

        	
           

        	
           

        	
          0.320

        	
           

        	
           

        	
           

        	
          0.333

        	
           

        	
           

        	
           

        	
          0.346

        	
           

        	
           

        	
           

        	
          0.357

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          48 months

        	
           

        	
           

        	
          0.241

        	
           

        	
           

        	
           

        	
          0.263

        	
           

        	
           

        	
           

        	
          0.283

        	
           

        	
           

        	
           

        	
          0.301

        	
           

        	
           

        	
           

        	
          0.317

        	
           

        	
           

        	
           

        	
          0.332

        	
           

        	
           

        	
           

        	
          0.344

        	
           

        	
           

        	
           

        	
          0.356

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          45 months

        	
           

        	
           

        	
          0.235

        	
           

        	
           

        	
           

        	
          0.258

        	
           

        	
           

        	
           

        	
          0.279

        	
           

        	
           

        	
           

        	
          0.298

        	
           

        	
           

        	
           

        	
          0.315

        	
           

        	
           

        	
           

        	
          0.330

        	
           

        	
           

        	
           

        	
          0.343

        	
           

        	
           

        	
           

        	
          0.356

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          42 months

        	
           

        	
           

        	
          0.228

        	
           

        	
           

        	
           

        	
          0.252

        	
           

        	
           

        	
           

        	
          0.274

        	
           

        	
           

        	
           

        	
          0.294

        	
           

        	
           

        	
           

        	
          0.312

        	
           

        	
           

        	
           

        	
          0.328

        	
           

        	
           

        	
           

        	
          0.342

        	
           

        	
           

        	
           

        	
          0.355

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          39 months

        	
           

        	
           

        	
          0.221

        	
           

        	
           

        	
           

        	
          0.246

        	
           

        	
           

        	
           

        	
          0.269

        	
           

        	
           

        	
           

        	
          0.290

        	
           

        	
           

        	
           

        	
          0.309

        	
           

        	
           

        	
           

        	
          0.325

        	
           

        	
           

        	
           

        	
          0.340

        	
           

        	
           

        	
           

        	
          0.354

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          36 months

        	
           

        	
           

        	
          0.213

        	
           

        	
           

        	
           

        	
          0.239

        	
           

        	
           

        	
           

        	
          0.263

        	
           

        	
           

        	
           

        	
          0.285

        	
           

        	
           

        	
           

        	
          0.305

        	
           

        	
           

        	
           

        	
          0.323

        	
           

        	
           

        	
           

        	
          0.339

        	
           

        	
           

        	
           

        	
          0.353

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          33 months

        	
           

        	
           

        	
          0.205

        	
           

        	
           

        	
           

        	
          0.232

        	
           

        	
           

        	
           

        	
          0.257

        	
           

        	
           

        	
           

        	
          0.280

        	
           

        	
           

        	
           

        	
          0.301

        	
           

        	
           

        	
           

        	
          0.320

        	
           

        	
           

        	
           

        	
          0.337

        	
           

        	
           

        	
           

        	
          0.352

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          30 months

        	
           

        	
           

        	
          0.196

        	
           

        	
           

        	
           

        	
          0.224

        	
           

        	
           

        	
           

        	
          0.250

        	
           

        	
           

        	
           

        	
          0.274

        	
           

        	
           

        	
           

        	
          0.297

        	
           

        	
           

        	
           

        	
          0.316

        	
           

        	
           

        	
           

        	
          0.335

        	
           

        	
           

        	
           

        	
          0.351

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          27 months

        	
           

        	
           

        	
          0.185

        	
           

        	
           

        	
           

        	
          0.214

        	
           

        	
           

        	
           

        	
          0.242

        	
           

        	
           

        	
           

        	
          0.268

        	
           

        	
           

        	
           

        	
          0.291

        	
           

        	
           

        	
           

        	
          0.313

        	
           

        	
           

        	
           

        	
          0.332

        	
           

        	
           

        	
           

        	
          0.350

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          24 months

        	
           

        	
           

        	
          0.173

        	
           

        	
           

        	
           

        	
          0.204

        	
           

        	
           

        	
           

        	
          0.233

        	
           

        	
           

        	
           

        	
          0.260

        	
           

        	
           

        	
           

        	
          0.285

        	
           

        	
           

        	
           

        	
          0.308

        	
           

        	
           

        	
           

        	
          0.329

        	
           

        	
           

        	
           

        	
          0.348

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          21 months

        	
           

        	
           

        	
          0.161

        	
           

        	
           

        	
           

        	
          0.193

        	
           

        	
           

        	
           

        	
          0.223

        	
           

        	
           

        	
           

        	
          0.252

        	
           

        	
           

        	
           

        	
          0.279

        	
           

        	
           

        	
           

        	
          0.304

        	
           

        	
           

        	
           

        	
          0.326

        	
           

        	
           

        	
           

        	
          0.347

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          18 months

        	
           

        	
           

        	
          0.146

        	
           

        	
           

        	
           

        	
          0.179

        	
           

        	
           

        	
           

        	
          0.211

        	
           

        	
           

        	
           

        	
          0.242

        	
           

        	
           

        	
           

        	
          0.271

        	
           

        	
           

        	
           

        	
          0.298

        	
           

        	
           

        	
           

        	
          0.322

        	
           

        	
           

        	
           

        	
          0.345

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          15 months

        	
           

        	
           

        	
          0.130

        	
           

        	
           

        	
           

        	
          0.164

        	
           

        	
           

        	
           

        	
          0.197

        	
           

        	
           

        	
           

        	
          0.230

        	
           

        	
           

        	
           

        	
          0.262

        	
           

        	
           

        	
           

        	
          0.291

        	
           

        	
           

        	
           

        	
          0.317

        	
           

        	
           

        	
           

        	
          0.342

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          12 months

        	
           

        	
           

        	
          0.111

        	
           

        	
           

        	
           

        	
          0.146

        	
           

        	
           

        	
           

        	
          0.181

        	
           

        	
           

        	
           

        	
          0.216

        	
           

        	
           

        	
           

        	
          0.250

        	
           

        	
           

        	
           

        	
          0.282

        	
           

        	
           

        	
           

        	
          0.312

        	
           

        	
           

        	
           

        	
          0.339

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          9 months

        	
           

        	
           

        	
          0.090

        	
           

        	
           

        	
           

        	
          0.125

        	
           

        	
           

        	
           

        	
          0.162

        	
           

        	
           

        	
           

        	
          0.199

        	
           

        	
           

        	
           

        	
          0.237

        	
           

        	
           

        	
           

        	
          0.272

        	
           

        	
           

        	
           

        	
          0.305

        	
           

        	
           

        	
           

        	
          0.336

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          6 months

        	
           

        	
           

        	
          0.065

        	
           

        	
           

        	
           

        	
          0.099

        	
           

        	
           

        	
           

        	
          0.137

        	
           

        	
           

        	
           

        	
          0.178

        	
           

        	
           

        	
           

        	
          0.219

        	
           

        	
           

        	
           

        	
          0.259

        	
           

        	
           

        	
           

        	
          0.296

        	
           

        	
           

        	
           

        	
          0.331

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          3 months

        	
           

        	
           

        	
          0.034

        	
           

        	
           

        	
           

        	
          0.065

        	
           

        	
           

        	
           

        	
          0.104

        	
           

        	
           

        	
           

        	
          0.150

        	
           

        	
           

        	
           

        	
          0.197

        	
           

        	
           

        	
           

        	
          0.243

        	
           

        	
           

        	
           

        	
          0.286

        	
           

        	
           

        	
           

        	
          0.326

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        
	
          0 months

        	
           

        	
           

        	
          —

        	
           

        	
           

        	
           

        	
          —

        	
           

        	
           

        	
           

        	
          0.042

        	
           

        	
           

        	
           

        	
          0.115

        	
           

        	
           

        	
           

        	
          0.179

        	
           

        	
           

        	
           

        	
          0.233

        	
           

        	
           

        	
           

        	
          0.281

        	
           

        	
           

        	
           

        	
          0.323

        	
           

        	
           

        	
           

        	
          0.361

        	
           

        

  
    12 

    
      
 

  

   

  The exact Redemption Fair Market Value and Redemption Date may not be set forth in the table above, in which case, if the
    Redemption Fair Market Value is between two values in the table or the Redemption Date is between two redemption dates in the table, the number of shares of Common Stock to be issued for each Warrant exercised in a Make-Whole Exercise shall be
    determined by a straight-line interpolation between the number of shares set forth for the higher and lower Redemption Fair Market Values and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.

   

  The stock prices set forth in the column headings of the table above shall be adjusted as of any date on which the number of
    shares issuable upon exercise of a Warrant or the Warrant Price is adjusted pursuant to Section 4 hereof. If the number of shares issuable upon exercise of a Warrant is adjusted pursuant to Section 4 hereof, the adjusted share prices in
    the column headings shall equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a Warrant immediately prior to such adjustment and the
    denominator of which is the number of shares deliverable upon exercise of a Warrant as so adjusted. The number of shares in the table above shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a
    Warrant. If the Warrant Price is adjusted, (a) in the case of an adjustment pursuant to Section 4.4 hereof, the adjusted share prices in the column headings shall equal the share prices immediately prior to such adjustment multiplied by a
    fraction, the numerator of which is the higher of the Market Value and the Newly Issued Price and the denominator of which is $10.00 and (b) in the case of an adjustment pursuant to Section 4.1.2 hereof, the adjusted share prices in the column
    headings shall equal the share prices immediately prior to such adjustment less the decrease in the Warrant Price pursuant to such Exercise Price adjustment. In no event shall the Warrants be exercisable in connection with a Make-Whole Exercise for
    more than 0.361 shares of Common Stock per Warrant (subject to adjustment). In the event that the stock prices set forth under the column headings of the above table are adjusted as provided in the preceding sentences of this paragraph, then the
    references to “0.361” appearing in the immediately preceding sentence and in subsection 7.4.1 shall be simultaneously adjusted to be equal to the number appearing in the $18.00 column of such table immediately after giving effect to such adjustment to
    the stock prices in such table; and, in the event that the stock prices set forth under the column headings of such table are subsequently adjusted as provided in the preceding sentences of this paragraph, then the number in the immediately preceding
    sentence and in subsection 7.4.1 shall again be adjusted as provided in this sentence. 

   

  6.3         Date Fixed for, and Notice of, Redemption; Redemption Price; Reference Value. In the event that the Company
    elects to redeem the Warrants pursuant to Sections 6.1 or 6.2, the Company shall fix a date for the redemption (the “Redemption Date”). Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not
    less than thirty (30) days prior to the Redemption Date (the period lasting from such time until the Redemption Date, the “30-day Redemption Period”) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall
    appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the Registered Holder received such notice. As used in this Agreement, (a) “Redemption Price”
    shall mean the price per Warrant at which any Warrants are redeemed pursuant to Sections 6.1 or 6.2 and (b) “Reference Value” shall mean the last reported sales price of the Common Stock for any twenty (20) trading days within
    the thirty (30) trading day period ending on the third trading day prior to the date on which notice of the redemption is given.

   

  6.4             Exercise After Notice of Redemption. The Warrants may be exercised, for cash (or, if in connection with
    a redemption pursuant to Section 6.2 of this Agreement, on a “cashless basis” in accordance with such section) at any time after notice of redemption shall have been given by the Company pursuant to Section 6.3 hereof and prior to the
    Redemption Date. On and after the Redemption Date, the Registered Holder of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.

   

  
    13 

    
      
 

  

   

  6.5             Exclusion of Private Placement Warrants. The Company agrees that (a) the redemption rights provided in
    Section 6.1 hereof shall not apply to the Private Placement Warrants if at the time of the redemption such Private Placement Warrants continue to be held by the Sponsor or its Permitted Transferees and (b) if the Reference Value equals or
    exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof), the redemption rights provided in Section 6.2 hereof shall not apply to the Private Placement Warrants if at the time of the redemption such Private
    Placement Warrants continue to be held by the Sponsor or its Permitted Transferees. However, once such Private Placement Warrants are transferred (other than to Permitted Transferees in accordance with Section 2.6 hereof), the Company shall
    redeem the Private Placement Warrants pursuant to Section 6.1 or 6.2 hereof, if the Company elects to redeem the Warrants pursuant to either such Section, provided that the criteria for redemption are met, including the opportunity of
    the holder of such Private Placement Warrants to exercise the Private Placement Warrants prior to redemption pursuant to Section 6.4 hereof. Private Placement Warrants that are transferred to persons other than Permitted Transferees shall upon
    such transfer cease to be Private Placement Warrants and shall become Public Warrants under this Agreement, including for purposes of Section 9.8 hereof.

   

  7.                 Other Provisions Relating to Rights of Holders of Warrants.

   

  7.1             No Rights as Stockholder. A Warrant does not entitle the Registered Holder thereof to any of the rights
    of a stockholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as stockholders in respect of the meetings of stockholders
    or the election of directors of the Company or any other matter.

   

  7.2          Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed,
    the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor,
    and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time
    enforceable by anyone.

   

  7.3             Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its
    authorized but unissued shares of Common Stock that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

   

  7.4             Registration of Common Stock; Cashless Exercise at Company’s Option.

   

  7.4.1       Registration of the Common Stock. The Company agrees that as soon as practicable, but in no event later
    than fifteen (15) Business Days after the closing of its initial Business Combination, it shall use its commercially reasonable efforts to file with the Commission a registration statement for the registration, under the Securities Act, of the issuance
    of the shares of Common Stock issuable upon exercise of the Warrants. The Company shall use its commercially reasonable efforts to cause the same to become effective within sixty (60) Business Days following the closing of its initial Business
    Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration or redemption of the Warrants in accordance with the provisions of this Agreement. If any such registration
    statement has not been declared effective by the sixtieth (60th) Business Day following the closing of the Business Combination, holders of the Warrants shall have the
    right, during the period beginning on the sixty-first (61st) Business Day after the closing of the Business Combination and ending upon such registration statement being
    declared effective by the Commission, and during any other period when the Company shall fail to have maintained an effective registration statement covering the issuance of shares of Common Stock issuable upon exercise of the Warrants and a current
    prospectus relating thereto, to exercise such Warrants on a “cashless basis,” by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act (or any successor thereto) or another exemption) for that number of shares of Common
    Stock equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Warrant Price by (y) the
    Fair Market Value and (B) the product of 0.361 multiplied by the number of shares of Common Stock underlying the Warrants. Solely for purposes of this subsection 7.4.1, “Fair Market Value” shall mean the volume-weighted average price of the
    Common Stock for the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants or its securities broker or intermediary. The date that notice of
    “cashless exercise” is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless exercise” of a Public Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of
    counsel for the Company (which shall be an outside law firm with securities law experience) to the effect that (i) the exercise of the Warrants on a “cashless basis” in accordance with this subsection 7.4.1 is not required to be registered
    under the Securities Act and (ii) the shares of Common Stock issued upon such exercise shall be tradable without registration under the Securities Act by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act) of
    the Company and, accordingly, shall not be required to bear a restrictive legend, or otherwise reasonably acceptable to the Warrant Agent. Except as provided in subsection 7.4.2, for the avoidance of doubt, unless and until all of the Warrants
    have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences of this subsection 7.4.1. At such time as the Warrants become exercisable for a security
    other than shares of Common Stock, the Company (or, if applicable, the successor or surviving entity) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the Warrants.

   

  
    14 

    
      
 

  

   

  7.4.2       Cashless Exercise at Company’s Option. If the Common Stock is at the time of any exercise of a Public
    Warrant not listed on a national securities exchange such that it does not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act (or any successor thereto), the Company may, at its option, (i) require holders of
    Public Warrants who exercise Public Warrants to exercise such Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act (or any successor thereto) as described in subsection 7.4.1 and (ii) in the event the
    Company so elects, the Company shall (x) not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the Common Stock issuable upon exercise of the Warrants, notwithstanding anything in this
    Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify for sale the Common Stock issuable upon exercise of the Public Warrant under applicable blue sky laws to the extent an exemption is not available. Upon
    receipt of a notice of exercise for a cashless exercise the Company will promptly calculate and transmit to the Warrant Agent the number of shares of Common Stock issuable in connection with such cashless exercise and deliver a copy of the notice of
    exercise to the Warrant Agent, which shall issue such number of shares of Common Stock in connection with such cashless exercise.

   

  7.4.3       State Securities Laws. Anything herein to the contrary notwithstanding, the Company will use its
    commercially reasonable efforts to register or qualify the Common Stock issuable upon the exercise of the Warrants under applicable state securities laws to the extent an exemption from such registration or qualification is not available (including,
    without limitation, the exemption available so long as the Common Stock is a “covered security” under (A) Section 18(b)(1) of the Securities Act or (B) solely in the case of shares of Common Stock being issued upon cashless exercise of a Warrant (if
    such cashless exercise is permitted under this Agreement), Section 18(b)(4)(E) of the Securities Act, provided that, in the case of this clause (B), such Warrant is being exercised pursuant and in accordance with Section 3(a)(9) of the
    Securities Act).

   

  
    15 

    
      
 

  

   

  8.                 Concerning the Warrant Agent and Other Matters.

   

  8.1             Payment of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be
    imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Common Stock upon the exercise of the Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares
    of Common Stock.

   

  8.2             Resignation, Consolidation, or Merger of Warrant Agent.

   

  8.2.1       Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may
    resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise,
    the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity
    by the Warrant Agent or by the holder of a Warrant (who shall, with such notice, submit his Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for
    the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing
    and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any
    successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed;
    but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such
    predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor
    Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

   

  8.2.2       Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company
    shall give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Common Stock not later than the effective date of any such appointment.

   

  8.2.3       Merger or Consolidation of Warrant Agent. Any entity into which the Warrant Agent may be merged or with
    which it may be consolidated or any entity resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.

   

  8.3             Fees and Expenses of Warrant Agent.

   

  8.3.1       Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such
    Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

   

  8.3.2       Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be
    performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.

   

  
    16 

    
      
 

  

   

  8.4             Liability of Warrant Agent.

   

  8.4.1       Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant
    Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically
    prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, President, Chief Financial Officer, Secretary or Chairman of the Board of the Company and delivered to the Warrant Agent. The
    Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

   

  8.4.2       Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful
    misconduct, fraud or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, out-of-pocket costs and reasonable outside counsel fees, for anything done or omitted by the
    Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct, fraud or bad faith.

   

  8.4.3       Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement
    or with respect to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The
    Warrant Agent shall not be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would
    require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether
    any shares of Common Stock shall, when issued, be valid and fully paid and non-assessable.

   

  8.5             Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and
    agrees to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the
    Warrant Agent for the purchase of shares of Common Stock through the exercise of the Warrants.

   

  8.6             Waiver. The Warrant Agent has no right of set-off or any other right, title, interest or claim of any
    kind (“Claim”) in, or to any distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and the Warrant Agent as trustee thereunder) and hereby
    agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to
    the Trust Account.

   

  9.                  Miscellaneous Provisions.

   

  9.1             Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or
    the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.

   

  
    17 

    
      
 

  

   

  9.2             Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the
    Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice,
    postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows:

   

  Jackson Acquisition Company

    2655 Northwinds Parkway

    Alpharetta, GA 30009

    Attention: Richard L. Jackson

   

  Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the
    Company to or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed
    (until another address is filed in writing by the Warrant Agent with the Company), as follows:

   

  Continental Stock Transfer & Trust Company

    1 State Street, 30 FL

    New York, New York 10004

    Attn:   Compliance Department

   

  9.3             Applicable Law and Exclusive Forum. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in
    all respects by the laws of the State of New York. Subject to applicable law, the Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement, including under the Securities Act, shall
    be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive forum for any such action,
    proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce
    any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum.

   

  Any person or entity purchasing or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to
    have consented to the forum provisions in this Section 9.3. If any action, the subject matter of which is within the scope of the forum provisions above, is filed in a court other than a court of the State of New York or the United States District
    Court for the Southern District of New York (a “foreign action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State
    of New York in connection with any action brought in any such court to enforce the forum provisions (an “enforcement action”), and (y) having service of process made upon such warrant holder in any such enforcement action by service upon such
    warrant holder’s counsel in the foreign action as agent for such warrant holder.

   

  9.4             Persons Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer
    upon, or give to, any person, corporation or other entity other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or
    agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the Registered Holders of the
    Warrants.

   

  
    18 

    
      
 

  

   

  9.5             Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable
    times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit such holder’s Warrant for inspection by
    it.

   

  9.6             Counterparts. This Agreement may be executed in any number of original or facsimile counterparts, and
    each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. The words “executed”, “execution,” “signed,” “signature,” and words of like import in
    this Agreement or in any certificate, agreement or document related to this Agreement shall include images of manually executed signatures transmitted by facsimile, email or other electronic format (including, without limitation, “pdf,” “tif” or “jpg”)
    but shall not include (nor shall this Agreement or any Warrant be executed or countersigned by means of) electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of signatures transmitted electronically and electronic
    records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use
    of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable
    law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code.

   

  9.7             Effect of Headings. The section headings herein are for convenience only and are not part of this
    Agreement and shall not affect the interpretation thereof.

   

  9.8      Amendments. This Agreement may be amended by the parties hereto without the consent of any Registered Holder
    for the purpose of (i) curing any ambiguity or correcting any mistake, including conforming the provisions hereof to the description of the terms of the Warrants and this Agreement set forth in the Prospectus, or defective provision contained herein,
    or (ii) adding or changing any provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the rights of the Registered Holders under
    this Agreement. All other modifications or amendments, including any modification or amendment to increase the Warrant Price or shorten the Exercise Period and any amendment to the terms of only the Private Placement Warrants, shall require the vote or
    written consent of the Registered Holders of at least 65% of the then outstanding Public Warrants; provided that any amendment that solely affects the terms of the Private Placement Warrants or any provision of this Agreement solely with
    respect to the Private Placement Warrants shall also require at least 65% of the-then outstanding Private Placement Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period pursuant
    to Sections 3.1 and 3.2, respectively, without the consent of the Registered Holders.

   

  9.9             Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any
    term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall
    be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

   

  
    19 

    
      
 

  

   

  IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

   

  	
           

        	
          JACKSON ACQUISITION COMPANY

        
	
           

        	
           

        	
           

        	
           

        
	
           

        	
          By:

        	
           

        	
           

        
	
           

        	
           

        	
          Name:

        	
          Richard L. Jackson

        
	
           

        	
           

        	
          Title:

        	
          President and Chief Executive Officer

        
	
           

        	
           

        	
           

        	
           

        
	
           

        	
           

        	
           

        	
           

        
	
           

        	
          Continental Stock Transfer & Trust Company, as Warrant Agent

        
	
           

        	
           

        	
           

        	
           

        
	
           

        	
          By:

        	
           

        	
           

        
	
           

        	
           

        	
          Name:

        	
           

        
	
           

        	
           

        	
          Title:

        	
           

        

   

  

  [Signature Page to Warrant Agreement]

   

  
     

    
      
 

  

   

  EXHIBIT A

   

  Form of Warrant Certificate

   

  
     

    
      
 

  

   

  [Face of Warrant Certificate]

  Number

  Warrants

   

  THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO

        THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR

        IN THE WARRANT AGREEMENT DESCRIBED BELOW

   

  Jackson Acquisition Company

   

  Incorporated Under the Laws of the State of Delaware

   CUSIP 46653C 114

   

  Warrant Certificate

   

  This Warrant Certificate certifies that ___________, or registered assigns, is the registered holder of
    ___________ warrant(s) evidenced hereby (the “Warrants” and each, a “Warrant”) to purchase shares of Class A common stock, $0.0001 par value (“Common Stock”), of Jackson Acquisition Company, a Delaware corporation (the “Company”).

    Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and non-assessable shares of Common Stock as set forth below, at the exercise
    price (the “Exercise Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise” as provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant
    Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein
    shall have the meanings given to them in the Warrant Agreement.

   

  Each Warrant is initially exercisable for one fully paid and non-assessable share of Common Stock. No fractional shares of
    Common Stock will be issued upon exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in a share of Common Stock, the Company will, upon exercise, round down to the nearest whole number
    the number of shares of Common Stock to be issued to the Warrant holder. The number of shares of Common Stock issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

   

  The initial Exercise Price per share of Common Stock for any Warrant is equal to $11.50 per share. The Exercise Price is
    subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

   

  Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period
    and to the extent not exercised by the end of such Exercise Period, such Warrants shall become void. The Warrants may be redeemed, subject to certain conditions, as set forth in the Warrant Agreement.

   

  Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such
    further provisions shall for all purposes have the same effect as though fully set forth at this place.

   

  This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant
    Agreement.

   

  
     

    
      
 

  

   

  This Warrant Certificate shall be governed by and construed in accordance with the internal laws of the State of New York,
    without regard to conflicts of laws principles thereof.

   

  	
           

        	
          Jackson Acquisition Company

        
	
           

        	
           

        	
           

        
	
           

        	
          By:

        	
           

        
	
           

        	
           

        	
          Name:

        
	
           

        	
           

        	
          Title:

        
	
           

        	
           

        	
           

        
	
           

        	
          CONTINENTAL STOCK TRANSFER & TRUST COMPANY

        
	
           

        	
           

        	
           

        
	
           

        	
          By:

        	
           

        
	
           

        	
           

        	
          Name:

        
	
           

        	
           

        	
          Title:

        

  
     

    
      
 

  

   

  [Reverse of Warrant Certificate]

   

  The Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on
    exercise to receive shares of Common Stock and are issued or to be issued pursuant to a Warrant Agreement dated as of [•], 2021 (the “Warrant Agreement”), duly executed and delivered by the Company to Continental Stock Transfer & Trust
    Company, a New York corporation, as warrant agent (the “Warrant Agent”), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of
    rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words “holders” or “holder” meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the
    Warrant Agreement may be obtained by the holder hereof upon written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

   

  Warrants may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants
    evidenced by this Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed, together with payment of the Exercise Price as specified in the
    Warrant Agreement (or through “cashless exercise” as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised
    shall be less than the total number of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.

   

  Notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the
    time of exercise (i) a registration statement covering the issuance of the shares of Common Stock to be issued upon exercise is effective under the Securities Act and (ii) a prospectus thereunder relating to the shares of Common Stock is current,
    except through “cashless exercise” as provided for in the Warrant Agreement or another exemption from registration under the Securities Act.

   

  The Warrant Agreement provides that upon the occurrence of certain events the number of shares of Common Stock issuable upon
    exercise of the Warrants set forth on the face hereof and the Exercise Price may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a fractional interest in a share of Common
    Stock, the Company shall, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued to the holder of the Warrant.

   

  Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder
    thereof in person or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant
    Certificate or Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants.

   

  Upon due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new
    Warrant Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant
    Agreement, without charge except for any tax or other governmental charge imposed in connection therewith.

   

  
     

    
      
 

  

   

  The Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant
    Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant
    Agent shall be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a stockholder of the Company.

   

  
     

    
      
 

  

   

  Election to Purchase

        (To Be Executed Upon Exercise of Warrant)

   

  The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive
    _____________ shares of Common Stock and herewith tenders payment (which may be by cashless exercise) for such shares of Common Stock to the order of Jackson Acquisition Company (the “Company”) in the amount of $____________ in accordance with the
    terms hereof. The undersigned requests that a certificate for such shares of Common Stock be registered in the name of ___________________, whose address is _______________________ and that such shares of Common Stock be delivered to
    ___________________ whose address is _______________________. If said number of shares of Common Stock is less than all of the shares of Common Stock purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the
    remaining balance of such shares of Common Stock be registered in the name of , whose address is _______________________and that such Warrant Certificate be delivered to ___________________, whose address is _______________________.

   

  In the event that the Warrant has been called for redemption by the Company pursuant to Section 6.2 of the Warrant
    Agreement and a holder thereof elects to exercise its Warrant pursuant to a Make-Whole Exercise, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) or Section
      6.2 of the Warrant Agreement, as applicable.

   

  In the event that the Warrant is a Private Placement Warrant that is to be exercised on a “cashless” basis pursuant to subsection

      3.3.1(c) of the Warrant Agreement, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.

   

  In the event that the Warrant is to be exercised on a “cashless” basis pursuant to Section 7.4 of the Warrant
    Agreement, the number of shares of Common Stock that this Warrant is exercisable for shall be determined in accordance with Section 7.4 of the Warrant Agreement.

   

  In the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, and is being exercised through
    cashless exercise (i) the number of shares of Common Stock that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise and (ii) the holder hereof
    shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive shares of Common Stock. If said number
    of shares is less than all of the shares of Common Stock purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such shares of Common Stock be
    registered in the name of ___________________, whose address is _______________________and that such Warrant Certificate be delivered to ___________________, whose address is _______________________.

   

  [Signature Page Follows]

   

  
     

    
      
 

  

   

  Date: ___________________, 20__

   

  	
           

        	
           

        
	
           

        	
           

        
	
           

        	
          (Signature)

        
	
           

        	
           

        
	
           

        	
           

        
	
           

        	
          (Address)

        
	
           

        	
           

        
	
           

        	
           

        
	
           

        	
          (Tax Identification Number)

        

  Signature Guaranteed:

   

  THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS
    WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 (OR ANY SUCCESSOR RULE)).

   

  
     

    
      
 

  

   

  EXHIBIT B

   

  LEGEND

   

  “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES
    LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO
    ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG Jackson Acquisition Company (THE “COMPANY”), RJ Healthcare SPAC, LLC
    AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN THE
    RECITALS OF THE WARRANT AGREEMENT BETWEEN THE COMPANY AND Continental Stock Transfer & Trust Company, AS WARRANT AGENT (THE “WARRANT AGREEMENT”)) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED
    IN SECTION 2 OF THE WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

   

  SECURITIES EVIDENCED BY THIS CERTIFICATE AND SHARES OF CLASS A COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE
    ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.”

   

  	
           

        	
           

        	
           

        
	
          No.

        	
           

        	
          WarrantExhibit 10.2

  

  

  Jackson Acquisition Company

  2655 Northwinds Parkway

  Alpharetta, GA 30009

  

  

  Re: Initial Public Offering

  

  

  Ladies and Gentlemen:

  

  

  This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and between Jackson Acquisition Company, a Delaware corporation (the “Company”), and BofA Securities, Inc., as underwriter (the “Underwriter”), relating to an underwritten initial public offering (the “Public Offering”) of up to 34,500,000 of the Company’s units (the “Units”)

    (including up to 4,500,000 units that may be purchased to cover over-allotments, if any, at the option of the Underwriter (the “over-allotment option”)), each comprised of one share of the Company’s Class A
    common stock, par value $0.0001 per share (the “Common Stock”), and one-third of one redeemable warrant. Each whole warrant (a “Warrant”) entitles the holder thereof to
    purchase one share of Common Stock at a price of $11.50 per share, subject to adjustment. The Units will be sold in the Public Offering pursuant to a registration statement on Form S-1 and prospectus (the “Prospectus”)

    filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”), and the Company has applied to have the Units listed on the New York Stock Exchange. Certain capitalized terms used herein
    are defined in paragraph 11 hereof.

  

  

  In order to induce the Company and the Underwriter to enter into the Underwriting Agreement and to proceed with the Public Offering and for other good and valuable
    consideration, the receipt and sufficiency of which are hereby acknowledged, RJ Healthcare SPAC, LLC (the “Sponsor”) and each of the undersigned individuals, each of whom is a member of the Company’s board of
    directors and/or an officer of the Company (each, an “Insider” and collectively, the “Insiders”), each hereby severally (and not jointly) agrees with the Company as
    follows:

  

  

  1.          The Sponsor and each Insider agrees that if the Company seeks stockholder approval
      of a proposed Business Combination, then in connection with such proposed Business Combination, it, he or she shall (i) vote any shares of Capital Stock owned by it, him or her in favor of any proposed Business Combination and (ii) not redeem any
      shares of Capital Stock owned by it, him or her in connection with such stockholder approval. If the Company seeks to consummate a proposed Business Combination by engaging in a tender offer for Common Stock, the Sponsor and each Insider agrees that
      it, he or she will not sell or tender any shares of Capital Stock owned by it, him or her in connection therewith. As used in this Letter Agreement, references to Capital Stock, Warrants or other securities "owned" by any person or entity and similar
      references mean any direct or indirect legal, record or beneficial ownership.

  

  

  2.          The Sponsor and each Insider hereby agrees that in the event that the Company fails
      to consummate its initial Business Combination within 24 months from the closing of the Public Offering, or such later period approved by the Company’s stockholders in accordance with the Company’s amended and restated certificate of incorporation
      (the “Charter”), the Sponsor and each Insider shall take all reasonable steps to cause the Company to (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but
      not more than 10 business days thereafter, subject to lawfully available funds therefor, redeem 100% of the Common Stock sold as part of the Units in the Public Offering (the “Offering Shares”), at a per-share
      price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of
      then issued and outstanding Offering Shares, which redemption will completely extinguish all Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii)
      as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under
      Delaware law to provide for claims of creditors and the requirements of other applicable law. The Sponsor and each Insider agree to not propose any amendment to the Charter (A) that would modify the substance or timing of the Company’s obligation to
      allow redemption of the Offering Shares in connection with the Company’s initial Business Combination or to redeem 100% of the Offering Shares if the Company does not complete its initial Business Combination within 24 months from the closing of the
      Public Offering, or (B) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provides its Public Stockholders with the opportunity to redeem their Offering Shares upon
      approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and
      outstanding Offering Shares.

  

  

  
    

    1

    
      

    

  

  

  

  The Sponsor and each Insider acknowledges and agrees that it, he or she has no right, title, interest or claim of any kind in or to any monies held in, or any liquidating
    distributions from, the Trust Account as a result of any liquidation of the Company with respect to the Founder Shares held by it, him or her at any time and, without limitation of the foregoing, waives any such right, title, interest or claim. The
    Sponsor and each Insider hereby further waives, with respect to any shares of Capital Stock held by it, him or her, if any, at any time, any redemption rights it, he or she may have in connection with (x) the consummation of a Business Combination,
    including, without limitation, any such rights available in the context of a stockholder vote to approve such Business Combination or in the context of a tender offer made by the Company to purchase shares of Common Stock and (y) a stockholder vote to
    approve an amendment to the Charter (i) to modify the substance or timing of the Company’s obligation to allow redemption of Offering Shares in connection with the Company’s initial Business Combination or to redeem 100% of the Offering Shares if the
    Company does not complete a Business Combination within 24 months of the closing of the Public Offering or (ii) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity (although the Sponsor, the
    Insiders and their respective affiliates shall be entitled to redemption and liquidation rights with respect to any Offering Shares it or they hold if the Company fails to consummate a Business Combination within 24 months from the closing of the
    Public Offering).

  

  

  3.          Without limitation to the provisions set forth in paragraphs 7(a) and (b) below,
      during the period beginning on and including the date of the Underwriting Agreement through and including the day that is 180 days after such date, the Sponsor and each Insider will not, without the prior written consent of the Underwriter, directly
      or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any Units, shares of
      Capital Stock, Warrants, Working Capital Warrants, Private Placement Warrants or other warrants of the Company or any securities convertible into, or exercisable or exchangeable for, Units, shares of Capital Stock, Warrants, Working Capital Warrants,
      Private Placement Warrants or other warrants of the Company, or file or confidentially submit or cause to be filed or confidentially submitted any registration statement under the Securities Act of 1933, as amended (the “Securities Act”), with respect to any of the foregoing securities or register any of the foregoing securities pursuant to a registration statement filed under the Securities Act , or publicly disclose any intention to undertake any of
      the foregoing, or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, any of the economic consequences of ownership of any Units, shares of Capital Stock, Warrants, Working
      Capital Warrants, Private Placement Warrants or other warrants of the Company, whether any such swap, agreement  or transaction described in clause (i) or (ii) above is to be settled by delivery of Units, shares of Capital Stock, Warrants, Working
      Capital Warrants, Private Placement Warrants, other warrants of the Company or other securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the forfeiture of Founder Shares if the Underwriter does not exercise its
      over-allotment option in full, (B) any transfer of Founder Shares to any current or future independent directors of the Company (so long as each such current or future independent director is, at the time of such transfer, a party to this Letter
      Agreement or a written agreement (which may be an amendment or supplement to this Letter Agreement or a substantially identical agreement) delivered to the Company prior to such transfer agreeing to be bound by and comply with all of the terms and
      provisions of this Letter Agreement that are applicable to Insiders (including, without limitation, the transfer restrictions set forth in this paragraph 3 and paragraph 7 hereof), and making the representations and warranties set forth in this
      Letter Agreement that are made by Insiders; (C) any offer of securities that may be issued by the Company in connection with a Business Combination if such offer is made on behalf of the Company, or (D) any transfer of Founder Shares or Private
      Placement Warrants, or any shares of Common Stock issued or issuable upon the conversion of Founder Shares, to any Permitted Transferee (as defined below) described in, and in accordance with,any of clauses (c), (d), (e), (f) or (h) of paragraph 7(c)
      hereof (provided, however, that , in the case of any transfer pursuant to any of clauses (c)-(e) of paragraph 7(c), the transferee is, at the time of such transfer, a party to this Letter Agreement or enters into and delivers to the Company, at or
      prior to the time of such transfer, a written agreement (which may be an amendment or supplement to this Letter Agreement or a substantially identical agreement) agreeing to be bound by and comply with all of the terms and provisions of this Letter
      Agreement that are applicable to Insiders (or, if such transferee is the Sponsor, that are applicable to the Sponsor) (including, without limitation, the transfer restrictions set forth in this paragraph 3 and paragraph 7 hereof), and, if such
      transferee is the Sponsor or an officer or director of the Company, making applicable representations and warranties set forth in this Letter Agreement; provided, however, that, to the extent that any reporting obligation under Section 16 of the
      Securities Exchange Act of 1934, as amended, is triggered as a result of any transfer described in clause (A), (B) or (D) of this sentence, any related filing under such Section 16 includes a practical explanation as to the nature of the transfer). "Working Capital Warrants" means any warrants to purchase capital stock issued by the Company upon the conversion of working capital loans (“Working Capital Loans”) made to
      the Company by the Sponsor, any Insiders, or their respective affiliates.

  

  

  
    

    2

    
      

    

  

  

  

  4.          In the event of the liquidation of the Trust Account, the Sponsor (which for
      purposes of clarification shall not extend to any other shareholders, members, officers or managers of the Sponsor) agrees to indemnify and hold harmless the Company against any and all loss, liability, claim, damage and expense whatsoever
      (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, whether pending or threatened, or any claim whatsoever) to which the Company may become subject
      as a result of any claim by (i) any third party for services rendered (other than the Company’s independent registered public accountants) or products sold to the Company or (ii) a prospective target business with which the Company has discussed
      entering into a transaction agreement (a “Target”); provided, however, that such indemnification of the Company by the Sponsor shall apply only to the extent necessary to ensure that such claims by a third
      party for services rendered (other than the Company’s independent registered public accountants) or products sold to the Company or a Target do not reduce the amount of funds in the Trust Account to below (i) $10.00 per Offering Share or (ii) such
      lesser amount per Offering Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets (in each case, net of the amount of interest earned on the property in the Trust
      Account which may be withdrawn to pay taxes), except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the Underwriter
      against certain liabilities, including liabilities under the Securities Act of 1933, as amended, pursuant to the Underwriting Agreement. In the event that any such executed waiver is deemed to be unenforceable against such third party, the Sponsor
      shall not be responsible to the extent of any liability for such third party claims. The Sponsor shall have the right to defend against any such claim with counsel of its choice reasonably satisfactory to the Company if, within 15 days following
      written receipt of notice of the claim to the Sponsor, the Sponsor notifies the Company in writing that it shall undertake such defense. For the avoidance of doubt, none of the Company’s officers of directors will indemnify the Company for claims by
      third parties, including, without limitation, claims by vendors and prospective Targets.

  

  

  5.          To the extent that the Underwriter does not exercise in full its over-allotment
      option to purchase up to an additional 4,500,000 Units within 45 days from the date of the Prospectus (as further described in the Prospectus), the Sponsor agrees to forfeit, at no cost, a number of Founder Shares in the aggregate equal to the
      product of 1,125,000 multiplied by a fraction, (i) the numerator of which is 4,500,000 minus the number of Units, if any, purchased by the Underwriter upon the exercise of its over-allotment option, and (ii) the denominator of which is 4,500,000. The
      forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the Underwriter so that the aggregate number of outstanding Founder Shares will equal 20.0% of the Company’s total issued and outstanding shares of
      Capital Stock after the Public Offering. To the extent that the size of the Public Offering is increased or decreased, the Company will effect a recapitalization or share repurchase, redemption or stock split or other appropriate mechanism, as
      applicable, immediately prior to the consummation of the Public Offering in such amount as to maintain the number of outstanding Founder Shares at 20.0% of the total number of issued and outstanding shares of Capital Stock upon the consummation of
      the Public Offering. In connection with such increase or decrease in the size of the Public Offering, (A) references to 4,500,000 in the numerator and denominator of the formula in the first sentence of this paragraph shall be changed to a number
      equal to 15% of the number of shares of Common Stock included in the Units issued in the Public Offering (assuming no exercise of the over-allotment option), and (B) the reference to 1,125,000 in the formula set forth in the first sentence of this
      paragraph shall be adjusted to such number of Founder Shares that the Sponsor would have to return to the Company in order to hold (with all of the other holders of Founder Shares) an aggregate of 20.0% of the total number of issued and outstanding
      shares of Capital Stock upon consummation of the Public Offering (assuming no exercise of the over-allotment option).

  

  

  
    

    3

    
      

    

  

  

  

  6.          The Sponsor and each Insider hereby agrees and acknowledges that: (i) the
      Underwriter and the Company would be irreparably injured in the event of a breach by such Sponsor or an Insider of its, his or her obligations under paragraphs 1, 2, 3, 4, 5, 7(a), 7(b), and 9, as applicable, of this Letter Agreement, (ii) monetary
      damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall be entitled, to the extent permitted by applicable law, injunctive relief, in addition to any other remedy that such party may have in law or in equity, in
      the event of such breach.

  

  

  7.          (a) The Sponsor and each Insider agree that it, he or she shall not Transfer (as
      defined below) any Founder Shares (or shares of Common Stock issued or issuable upon conversion thereof) until the earlier of (A) one year after the completion of the Company’s initial Business Combination and (B) subsequent to the initial Business
      Combination, (x) if the last reported sale price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20
      trading days within any 30-trading day period commencing at least 150 days after the Company’s initial Business Combination or (y) the date on which the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar
      transaction that results in all of the Public Stockholders having the right to exchange their shares of Common Stock for cash, securities or other property (the “Founder Shares Lock-up Period”).

  

  

  (b)          The Sponsor and each Insider agree that it, he or she shall not Transfer any
      Private Placement Warrants (or shares of Common Stock issued or issuable upon the exercise of the Private Placement Warrants) until 30 days after the completion of the initial Business Combination (the “Private
        Placement Warrants Lock-up Period”, together with the Founder Shares Lock-up Period, the “Lock-up Periods”).

  

  

  (c)          Notwithstanding the provisions set forth in paragraphs 7(a) and (b), Transfers of
      the Founder Shares, Private Placement Warrants and shares of Common Stock issued or issuable upon the exercise or conversion of the Private Placement Warrants or Founder Shares and that are held by the Sponsor, any Insider or any of their Permitted
      Transferees (that have complied with this paragraph 7(c)), are permitted (a) to the Company’s officers or directors, any affiliates or family members of any of the Company’s officers or directors, the Sponsor, any members of the Sponsor, or any
      affiliates of the Sponsor; (b) in the case of an individual, by gift to a member of the individual’s immediate family, or to a trust, the beneficiary of which is a member of the individual’s immediate family or an affiliate of such person, or to a
      charitable organization; (c) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales or
      transfers made in connection with the consummation of the initial Business Combination at prices no greater than the price at which the securities were originally purchased; (f) in the event of the Company’s liquidation prior to the completion of an
      initial Business Combination; (g) by virtue of the laws of the State of Delaware or the Sponsor’s limited liability company agreement upon dissolution of the Sponsor; or (h) in the event of the Company’s completion of a liquidation, merger, share
      exchange, reorganization or other similar transaction which results in all of the Company’s Public Stockholders having the right to exchange their shares of Common Stock for cash, securities or other property subsequent to the completion of the
      initial Business Combination (the transferees referred to in clauses (a)-(h) above are called “Permitted Transferees”); provided, however, that, in the case of clauses (a)-(e) and clause (g) above, these
      Permitted Transferees must enter into and deliver to the Company, at or prior to the time of the applicable Transfer, a written agreement agreeing to be bound by the transfer restrictions set forth in paragraph 3 and this paragraph 7 and the other
      provisions of this Letter Agreement applicable to Insiders.

  

  

  8.          The Sponsor and each Insider represent and warrant that it, he or she has never
      been suspended or expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked. Each Insider’s biographical information furnished to the
      Company (including any such information included in the Prospectus) is true and accurate in all material respects and does not omit any material information with respect to the Insider’s background necessary to make such biographical information, in
      light of the circumstances in which such information is being presented in the Prospectus, not misleading. Each Insider’s questionnaire furnished to the Company is true and accurate in all material respects. Each Insider represents and warrants that:
      he or she is not subject to or a respondent in any legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction; he or she
      has never been convicted of, or pleaded guilty to, any crime (i) involving fraud, (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities and he or she is not currently
      a defendant in any such criminal proceeding.

  

  

  
    

    4

    
      

    

  

  

  

  9.          Except as disclosed in, or as expressly contemplated by, the Prospectus, neither
      the Sponsor nor any Insider nor any affiliate of the Sponsor or any Insider, nor any director or officer of the Company, shall receive from the Company any finder’s fee, reimbursement, consulting fee, monies in respect of any repayment of a loan or
      other compensation prior to, or in connection with, any services rendered in order to effectuate the consummation of the Company’s initial Business Combination (regardless of the type of transaction that it is). In the event that the Company shall
      issue any Working Capital Warrants upon conversion of any Working Capital Loans, not more than $1.5 million of such loans may be converted into Working Capital Warrants, such conversion shall only occur at or after the time the Business Combination
      is completed, the conversion price shall be $1.50 per Working Capital Warrant and such Working Capital Warrants shall be identical to the Private Placement Warrants, including, without limitation, as to exercise price, exercisability and exercise.

  

  

  10.          The Sponsor and each Insider has full right and power, without violating any
      agreement to which it, he or she is bound (including, without limitation, any non-competition or non-solicitation agreement with any employer or former employer), to enter into this Letter Agreement and, as applicable, to serve as an officer and/or a
      director on the board of directors of the Company and hereby consents to being named in the Prospectus as an officer and/or a director of the Company.

  

  

  11.          As used herein, (i) “Business Combination”
      shall mean a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving the Company and one or more businesses; (ii) “Capital Stock” shall mean,
      collectively, the Common Stock and the Founder Shares; (iii) ”Founder Shares” shall mean the 8,625,000 outstanding shares of the Company’s Class B common stock, par value $0.0001 per share, (up to 1,125,000 of
      which shares are subject to forfeiture if the Underwriter’s over-allotment option is not exercised by the Underwriter in whole or in part) (subject to adjustment to the numbers of shares in this clause (iii) pursuant to paragraph 5 of this Letter
      Agreement if the size of the Public Offering is increased or decreased); (iv) “Initial Stockholders” shall mean the Sponsor, the Insiders and any other holder of Founder Shares immediately prior to the
      consummation of the Public Offering; (v) “Private Placement Warrants” shall mean the warrants to purchase up to 5,666,667 shares of Common Stock (or 6,266,667 shares of Common Stock if the over-allotment option
      is exercised in full) that the Sponsor has agreed to purchase from the Company for an aggregate purchase price of approximately $8,500,000 in the aggregate (or approximately $9,400,000 if the over-allotment option is exercised in full), or $1.50 per
      warrant, in a private placement that shall occur simultaneously with the consummation of the Public Offering (subject to possible adjustment to the numbers of shares and dollar amounts (other than $1.50 per warrant) set forth in this clause (v) if
      the size of the Public Offering is increased or decreased); (vi) “Public Stockholders” shall mean the holders of Offering Shares; (vii) “Trust Account” shall mean the
      trust fund into which a portion of the net proceeds of the Public Offering and the sale of the Private Placement Warrants shall be deposited; and (viii) “Transfer” shall mean the (a) sale, transfer or
      assignment of, offer to sell, contract or agreement to sell, hypothecation, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, any Capital Stock, Private Placement Warrants or other
      securities of the Company, or the establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended,
      with respect to any Capital Stock, Private Placement Warrants or other securities of the Company, (b) entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any
      Capital Stock, Private Placement Warrants or other securities of the Company, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Capital Stock, Private Placement Warrants or other securities, in cash or
      otherwise, or (c) public announcement of any intention to effect any transaction specified in clause (a) or (b).

  

  

  12.          This Letter Agreement constitutes the entire agreement and understanding of the
      parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the
      transactions contemplated hereby. This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical error) as to any particular provision, except by a written instrument executed by (1) each Insider that is
      the subject of any such change, amendment, modification or waiver, (2) the Sponsor and (3) the Company.

  

  

  
    

    5

    
      

    

  

  

  

  13.          Except as otherwise provided herein, no party hereto may assign either this Letter
      Agreement or any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported assignment in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or
      assign any interest or title to the purported assignee. This Letter Agreement shall be binding on the Company, the Sponsor and each Insider and their respective successors, heirs and assigns and Permitted Transferees.

  

  

  14.          Nothing in this Letter Agreement shall be construed to confer upon, or give to,
      any person or entity other than the parties hereto any right, remedy or claim under or by reason of this Letter Agreement or of any covenant, condition, stipulation, promise or agreement hereof. All covenants, conditions, stipulations, promises and
      agreements contained in this Letter Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors, heirs, personal representatives and assigns and Permitted Transferees.

  

  

  15.          This Letter Agreement may be executed in any number of counterparts and each of
      such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. The words “executed”, “execution,” “signed,” “signature,” and words of like import in this
      Letter Agreement or in any certificate, agreement or document related to this Letter Agreement shall include images of manually executed signatures transmitted by facsimile, email or other electronic format (including, without limitation, “pdf,”
      “tif” or “jpg”) but shall not include (nor shall this Letter Agreement be executed by means of) electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of signatures transmitted electronically and electronic records
      (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a
      paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable
      law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code.

  

  

  16.          This Letter Agreement shall be deemed severable, and the invalidity or
      unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Letter Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the
      parties hereto intend, to the extent permitted by applicable law, that there shall be added as a part of this Letter Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.

  

  

  17.          This Letter Agreement shall be governed by and construed and enforced in
      accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. To the extent permitted by applicable law, the parties
      hereto (i) all agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in the courts of New York City, in the State of New York, and irrevocably submit to such
      jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.

  

  

  18.          Each party hereto shall not be liable for any breaches or misrepresentations
      contained in this Letter Agreement by any other party to this Letter Agreement (including, for the avoidance of doubt, any Insider with respect to any other Insider), and no party shall be liable or responsible for the obligations of another party,
      including, without limitation, indemnification obligations and notice obligations.

  

  

  19.          Any notice, consent or request to be given in connection with any of the terms or
      provisions of this Letter Agreement shall be in writing and shall be sent by express mail or similar private courier service, by certified mail (return receipt requested), by hand delivery or facsimile or other electronic transmission.

  

  

  20.          This Letter Agreement shall terminate on the earlier of (i) the expiration of the
      Lock-up Periods or (ii) the liquidation of the Company; provided, however, that this Letter Agreement shall earlier terminate in the event that the Public Offering is not consummated and closed (other than any exercise of the over-allotment option)
      by June 30, 2021; provided further that paragraph 4 of this Letter Agreement shall survive such liquidation for a period of six years.

  

  

  [Signature Page Follows]

  

  

  
    

    6

    
      

    

  

  

  

  Sincerely,

  

  

  RJ HEALTHCARE SPAC, LLC

  

  

  	 	 	 
	
          By:

        	 	 
	 	
          Name: Richard L. Jackson

        	 
	 	
          Title: Managing Member

        	 

  

  

  Insiders

  

  

  	 	 
	
          Name: John Ellis “Jeb” Bush

        	 
	 	 
	 	 
	
          Name: Richard L. Jackson

        	 
	 	 
	 	 
	
          Name: Douglas B. Kline

        	 
	 	 
	 	 
	
          Name: David A. Perdue, Jr.

        	 
	 	 
	 	 
	
          Name: Marilyn B. Tavenner

        	 
	 	 
	 	 
	
          Name: Carlos A. Migoya

        	 

  

  

  [Signature Page to Letter Agreement]

  
    

    
      

    

  

  Acknowledged and Agreed:

  

  

  JACKSON ACQUISITION COMPANY

  

  

  	
          By:

        	 	 
	 	
          Name: Richard L. Jackson

        	 
	 	
          Title:   President and Chief Executive Officer

        	 

  

  

  [Signature Page to Letter Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]